Arbutus Biopharma Corp (ABUS) stock
ABUSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 12/3081% below fair value
$4.09+0.06 (+1.49%)
Close on Nov 13, 2026Market cap $809.20MP/E 3.7Yield –
Arbutus Biopharma pe ratio
The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.
Arbutus Biopharma's pe ratio was 5.0× on Nov 11, 2026, against 2.6× a year earlier.
PE Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 5.0× | −1.8 |
| 2014 | Jan 31, 2014 | 6.7× | +2.9 |
| 2013 | Dec 31, 2013 | 3.9× | – |
See a number that looks wrong?